Zymeworks ROE 2016-2022 | ZYME
Current and historical return on equity (ROE) values for Zymeworks (ZYME) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Zymeworks ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2022-06-30 |
$-0.24B |
$0.22B |
-92.25% |
| 2022-03-31 |
$-0.24B |
$0.28B |
-85.23% |
| 2021-12-31 |
$-0.21B |
$0.25B |
-69.49% |
| 2021-09-30 |
$-0.21B |
$0.28B |
-61.14% |
| 2021-06-30 |
$-0.22B |
$0.32B |
-58.18% |
| 2021-03-31 |
$-0.20B |
$0.38B |
-45.61% |
| 2020-12-31 |
$-0.18B |
$0.41B |
-39.03% |
| 2020-09-30 |
$-0.22B |
$0.43B |
-50.86% |
| 2020-06-30 |
$-0.17B |
$0.49B |
-43.85% |
| 2020-03-31 |
$-0.16B |
$0.52B |
-45.89% |
| 2019-12-31 |
$-0.15B |
$0.25B |
-54.72% |
| 2019-09-30 |
$-0.06B |
$0.31B |
-25.75% |
| 2019-06-30 |
$-0.05B |
$0.33B |
-24.82% |
| 2019-03-31 |
$-0.03B |
$0.17B |
-17.00% |
| 2018-12-31 |
$-0.04B |
$0.18B |
-23.45% |
| 2018-09-30 |
$-0.01B |
$0.17B |
-9.17% |
| 2018-06-30 |
$-0.01B |
$0.19B |
-8.33% |
| 2018-03-31 |
$-0.02B |
$0.10B |
-15.35% |
| 2017-12-31 |
$-0.01B |
$0.12B |
-11.56% |
| 2017-09-30 |
$-0.05B |
$0.08B |
-72.48% |
| 2017-06-30 |
$-0.05B |
$0.10B |
-93.02% |
| 2017-03-31 |
$-0.05B |
$0.05B |
-155.93% |
| 2016-12-31 |
$-0.03B |
$0.07B |
-194.12% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.529B |
$0.412B |
|
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
|
